EPIC Act of 2025
Summary
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.EPIC Act equalizes small-molecule and biologic negotiation periods at 11 years starting 2028.
- 2.No direct federal spending—this is a regulatory delay of price negotiation, not a funding bill.
- 3.Primary beneficiaries are pharma companies with post-2028 small-molecule pipelines: MRK, PFE, GSK.
- 4.Bill is very early-stage (referred to committee, 7 cosponsors)—long legislative path ahead.
- 5.Current stock prices for MRK, PFE, GSK are all down 4-7% over 30 days, reflecting broader sector pressures unrelated to this bill.
Market Implications
Despite the 30-day declines in $MRK (-7.18% to $111.66), $PFE (-4.24% to $26.89), and $GSK (-5.02% to $52.42), the EPIC Act is a material structural positive for small-molecule pharma. Investors should view the current pullback as a potential entry point if legislative momentum builds. However, the bill is early-stage, and any near-term bounce would be speculative. Watch for: Senate Finance Committee markup, companion House bill introduction, and CBO score. The 2028 implementation date means no revenue impact for at least 2 years post-enactment, limiting near-term catalysts.
Full Analysis
-
WHAT HAPPENED: On March 4, 2025, Sen. Tillis (R-NC) introduced S.832, the EPIC Act of 2025, in the 119th Congress. The bill was read twice and referred to the Senate Committee on Finance. It has 7 cosponsors (all Republicans). The bill amends Section 1192(e)(1)(A)(ii) of the Social Security Act to extend the market approval period required before a small-molecule drug qualifies for Medicare price negotiation. For 2026-2027, the 7-year threshold remains. Starting in 2028, the threshold rises to 11 years—matching the current 11-year threshold for biologics.
-
THE MONEY TRAIL: This bill does not authorize or appropriate any direct federal spending. It is a regulatory change that defers mandatory price negotiation by four years per qualifying small-molecule drug. The financial impact is indirect: it preserves higher revenue for drug manufacturers on post-2028 approved small-molecule drugs by delaying CMS's ability to force discounts. No money leaves the Treasury due to this bill; rather, CMS's negotiation authority is postponed. The Congressional Budget Office would score this as a decrease in direct spending (Medicare pays more for drugs) and likely an increase in premiums.
-
STRUCTURAL WINNERS AND LOSERS: Winners are pharmaceutical companies with robust small-molecule pipelines expected to gain FDA approval after 2028. $MRK (Merck), $PFE (Pfizer), and $GSK (GSK) are primary beneficiaries given their large small-molecule R&D portfolios. $LLY (Eli Lilly) is also relevant though ticker not in provided data—its small-molecule pipeline includes obesity/diabetes candidates. Losers include CMS and Medicare beneficiaries who would wait longer for negotiated prices on new small-molecule drugs. Biosimilar and generic manufacturers are also disadvantaged as branded small-molecule exclusivity extends.
-
REAL MARKET DATA: As of April 30, 2026, $MRK trades at $111.66 (down 7.18% over 30 days, with a sharp drop from $119.07 on April 17). $PFE at $26.89 (down 4.24% over 30 days, declining steadily from $27.56). $GSK at $52.42 (down 5.02% over 30 days, with a notable drop from $54.47 on April 28 to $51.40 April 29). These declines occurred despite the bill being introduced—reflecting that the bill is early-stage and not a near-term catalyst. The market is pricing in other headwinds (patent cliffs, pipeline risks) rather than this legislative tailwind.
-
TIMELINE: The bill is in early-stage. It must pass the Senate Finance Committee (Chairman Grassley, R-IA has not publicly committed), then the full Senate, then the House (where a companion bill has not been introduced), and be signed by the President. With 7 Republican cosponsors and a 2028 implementation date, the bill has moderate low-term potential but faces significant hurdles this Congress given partisan disagreement over IRA drug pricing provisions.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Extends the minimum market approval period before a small-molecule drug qualifies for Medicare price negotiation from 7 to 11 years, effective for initial price applicability year 2028 and later.
Who must act
Centers for Medicare & Medicaid Services (CMS) under the Medicare Drug Price Negotiation Program
What happens
Small-molecule drugs approved after 2028 will have an additional 4 years of market exclusivity before facing mandatory price negotiation with CMS, delaying potential revenue erosion from government-set prices.
Stock impact
Merck's pipeline of small-molecule drugs (e.g., Keytruda is a biologic, but small-molecule candidates in oncology, cardiometabolic, and infectious disease) could see extended high-margin revenue windows. Merck had ~$12B in R&D spend in FY2025; small-molecule R&D is a significant portion. Delay of negotiation by 4 years per approved drug could preserve hundreds of millions in peak-year revenue per asset.
What the bill does
Extends the minimum market approval period before a small-molecule drug qualifies for Medicare price negotiation from 7 to 11 years, effective for initial price applicability year 2028 and later.
Who must act
Centers for Medicare & Medicaid Services (CMS) under the Medicare Drug Price Negotiation Program
What happens
Small-molecule drugs approved after 2028 will have an additional 4 years of market exclusivity before facing mandatory price negotiation with CMS, delaying potential revenue erosion from government-set prices.
Stock impact
Pfizer has a robust small-molecule pipeline spanning oncology, inflammation, vaccines (small-molecule adjuvants), and rare disease. Approximately 60% of Pfizer's revenue comes from small molecules. Delaying negotiation by 4 years per asset could protect $500M-$2B in revenue per blockbuster over the extended exclusivity window.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Americans from Unsafe Drugs Act of 2026
American Innovation and R&D Competitiveness Act of 2025
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Skinny Labels, Big Savings Act
Lowering Drug Costs for American Families Act
Most Favored Patient Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →